Drug Profile
Zika virus vaccine - Themis Bioscience
Alternative Names: MV-ZIKA; MV-Zika vaccine; MV-ZIKA-RSPLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Themis Bioscience
- Class Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for phase-I development in Zika-virus-infection(Prevention) in Austria (Parenteral)
- 13 Nov 2020 Zika virus vaccine is still in phase I trials for Zika virus infections in Austria (NCT04033068)
- 04 Nov 2020 Themis Bioscience completes a phase I trial in Zika virus infections in Austria (NCT04033068)